ViroCarb

ViroCarb is a biotechnology company dedicated to the development and commercialization of antiviral drugs aimed at addressing urgent unmet therapeutic needs in viral infections. The company operates in the biotech and pharmaceutical markets, focusing on creating innovative solutions for diseases that currently lack effective treatments. ViroCarb's primary clients include healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around the research and development of preclinical drug candidates, such as GPS 491, which has shown broad and potent activity against all HIV subtypes and clinical strains resistant to current therapies. The company collaborates with leading academics and research institutions, including the University of Toronto, University of British Columbia, and de Sherbrooke, to advance its drug development efforts. ViroCarb generates revenue through licensing agreements, partnerships, and eventual commercialization of its drug candidates. The company is led by a team of experienced scientists and business executives with a strong track record in drug discovery and development.

Keywords: antiviral drugs, biotechnology, HIV, GPS 491, unmet therapeutic needs, drug development, molecular genetics, medicinal chemistry, research collaboration, pharmaceutical market.